Drug intelligence / Profile preview

BXT-253

Development stage: Preclinical
Lead developer: BioXyTran
Modality: Recombinant Proteins and Enzymes
Administration: Parenteral

Overview

BXT-253 is a preclinical-stage therapeutic candidate being developed by BioXyTran for the treatment of anemia. It is a modified version of recombinant erythropoietin (EPO) produced using the company's proprietary De-Glycosylation and De-Sialylation (Deg-Des) platform. This enzymatic process removes sialic acid and galactose residues from the EPO molecule, a modification intended to alter its biological activity or pharmacokinetic profile. While asialoerythropoietin (asialo-EPO) is typically cleared rapidly by the liver and has been primarily investigated for its non-erythropoietic cytoprotective effects, BioXyTran is developing BXT-253 specifically for anemia, indicating a focus on its erythropoietin receptor agonist activity.

Targets

Erythropoietin Receptor

Beyond the preview

Go deeper on BXT-253.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BXT-253.

Explore the full profile